New drug aims to melt liver fat in NASH patients
NCT ID NCT05842512
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a drug called ADI-PEG 20 against a placebo in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive injections over 24 weeks, and doctors measure changes in liver fat using MRI. The goal is to see if the drug can safely reduce liver fat and improve the condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADI-PEG 20 (pegargiminase)
What this could lead to
If it works, this could point toward a new treatment for nonalcoholic steatohepatitis (NASH), a serious fatty liver disease.
What could go wrong
This is an early phase 2 trial with only 60 people, so results may not be conclusive. The drug may not reduce liver fat better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONALCOHOLIC STEATOHEPATITIS (NASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Medical Foundation-Kaohsiung (CGMF-KS)
RECRUITINGKaohsiung, Taiwan, 833, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chang Gung Medical Foundation-Keelung (CGMF-KL)
RECRUITINGKeelung, Taiwan, 204, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chang Gung Medical Foundation-Linkou (CGMF-LK)
RECRUITINGTaoyuan, Taiwan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ditmanson Medical Foundation Chiayi Christian Hospital；Chiayi Christian Hospital (CYCH)
RECRUITINGChiayi City, Taiwan, 600566, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
E-Da Hospital (EDH)
RECRUITINGKaohsiung, Taiwan, 824, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fu Jen Catholic University Hospital (FJCUH)
RECRUITINGTaipei, Taiwan, 243, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kaohsiung Medical University Chung-Ho Memorial Hospital(KMUH)
RECRUITINGKaohsiung, Taiwan, 807, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cheng Kung University Hospital (NCKUH)
RECRUITINGTainan, Taiwan, 704, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Hospital (NTUH)
RECRUITINGTaipei, Taiwan, 100229, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taipei Veterans General Hospital (TPVGH)
RECRUITINGTaipei, Taiwan, 112201, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••